Key Highlights
- AstraZeneca opens $20 million Global Hub in Bengaluru, adding 400 new jobs in AI, R&D, and digital health to drive clinical innovation.
- Investment supports the company’s global goal to launch 20 new medicines by 2030 through data-driven transformation.
- Follows $30 million expansion in Chennai, pushing India headcount to nearly 4,000 across two digital and innovation centers.
Strategic Investment to Scale AI-Driven Innovation
AstraZeneca has inaugurated a state-of-the-art Global Hub in Bengaluru with an investment of approximately $20 million (₹166 crore). The facility will host 1,300 professionals, including 400 new hires focused on AI, digital health, R&D, IT, and business services. The Bengaluru hub is designed to accelerate AstraZeneca’s ambition to deliver 20 new medicines by 2030 through scalable, automated, and patient-centric innovation.
Doubling Down on India’s Scientific Ecosystem
This marks AstraZeneca’s second major investment in India within a year—following a $30 million (₹250 crore) expansion of its Global Innovation and Technology Centre in Chennai. The combined expansion will increase AstraZeneca India’s workforce to nearly 4,000. Jackie Crockford, VP of Global Business Services, said this investment reflects the company’s commitment to leveraging India’s talent pool to power next-generation scientific discovery.
AI and Analytics to Drive Clinical Efficiency
The Bengaluru hub will play a critical role in building AI-enabled healthcare solutions, centralizing data analytics, and enhancing the efficiency of global clinical trials. Magnus Nord, VP of Global Patient Safety BioPharma, noted that this center enhances AstraZeneca’s R&D reach by tapping into India’s advanced technological and scientific capabilities.
Sustainability and Smart Infrastructure
Designed with sustainability at its core, the new Bengaluru facility is targeting LEED Platinum certification and currently operates on 75% green energy. It includes IoT-enabled energy systems, wastewater recycling, and eco-optimized infrastructure—demonstrating AstraZeneca’s dual focus on innovation and environmental responsibility.
By